Capricor Therapeutics, Inc. (CAPR) finds itself embroiled in securities law violation lawsuits, as announced on August 17. The biotechnology firm, with a market cap of $382M and no revenue, is facing scrutiny over its disclosures. Despite a recent stock surge, these legal challenges cast doubt on its management and transparency.
Fabrinet (FN) will report earnings after the close, putting focus on optical and networking hardware amid AI data-center growth. With a market cap of $20.4B, Fabrinet's performance could reflect broader sector trends. Investors are keen on insights into its positioning within the burgeoning AI infrastructure space.